The mechanistic target of rapamycin (mTOR) functions as a critical regulator of cellular growth and metabolism by forming multi-component, yet functionally distinct complexes mTORC1 and mTORC2. Although mTORC2 has been implicated in mTORC1 activation, little is known about how mTORC2 is regulated. Here we report that phosphorylation of Sin1 at Thr 86 and Thr 398 suppresses mTORC2 kinase activity by dissociating Sin1 from mTORC2. Importantly, Sin1 phosphorylation, triggered by S6K or Akt, in a cellular context-dependent manner, inhibits not only insulin-or IGF-1-mediated, but also PDGF-or EGF-induced Akt phosphorylation by mTORC2, demonstrating a negative regulation of mTORC2 independent of IRS-1 and Grb10. Finally, a cancer-patient-derived Sin1-R81T mutation impairs Sin1 phosphorylation, leading to hyper-activation of mTORC2 by bypassing this negative regulation. Together, our results reveal a Sin1-phosphorylation-dependent mTORC2 regulation, providing a potential molecular mechanism by which mutations in the mTORC1-S6K-Sin1 signalling axis might cause aberrant hyper-activation of the mTORC2-Akt pathway, which facilitates tumorigenesis.
consuming, regulation of mTORC1 activity is tightly coupled to the energy status of the cell and regulated by nutrients, energy, stress and growth factors, thereby ensuring that cells stop growing under unfavourable conditions 1, 8, 21, 22 .
Compared with well-defined mechanisms of mTORC1 activation such as mTORC2-Akt-mediated phosphorylation of TSC2 (refs 23, 24) or PRAS40 (refs 25,26) , the upstream signalling that governs mTORC2 activation is just beginning to be appreciated. To this end, the association of mTORC2 with the ribosome was recently found to be necessary for its activation 4 . Furthermore, mTORC1/S6Kmediated phosphorylation of IRS-1 (refs 27,28) and Grb10 (refs 28,29) also constitutes negative feedback mechanisms to block mTORC2 activation by insulin or IGF-1. However, both IRS-1 and Grb10 function by suppressing insulin or IGF-1 signalling upstream of phosphatidylinositol-3-OH kinase PI(3)K to affect both mTORC1 and mTORC2. Thus, it remains elusive whether mTORC1 could directly regulate the mTORC2-Akt pathway without broadly suppressing constructs. (f) In vitro kinase assays depicting major S6K phosphorylation sites in Sin1. Note that the GST-rictor fusion protein used here is not the full-length protein but rather the truncated version that contains the S6K phosphorylation site Thr 1135 (GST-rictor-C-tail (aa 1,390-1,708)). (g) Immunoblot analysis of WCL and anti-Flag immunoprecipitates derived from HeLa cells transfected with the indicated Flag-Sin1 constructs. Where indicated, cells were serum-starved for 12 h and stimulated by 100 nM insulin for 30 min before collection. (h) Immunoblot analysis of WCL and anti-Flag immunoprecipitates derived from HeLa cells depleted of raptor and transfected with Flag-Sin1 (GFP shRNA as a negative control). Where indicated, cells were serum-starved for 12 h and stimulated by the indicated stimuli before collecting. Uncropped images of blots are shown in Supplementary Fig. 9 .
the PI(3)K pathway and how mTORC1 suppresses mTORC2-Akt in stimulation conditions other than insulin or IGF-1.
Here we show that in response to a wide spectrum of stimuli including insulin, IGF-1, PDGF and EGF, phosphorylation of Sin1 dissociates Sin1 from mTORC2 to terminate mTORC2 kinase activity, revealing a negative regulation of mTORC2 function independent of the previously identified negative feedback regulators IRS-1 and Grb10 in suppressing mTORC2.
RESULTS

S6K phosphorylates Sin1 on both Thr 86 and Thr 398 sites
In keeping with previous reports [27] [28] [29] [30] , an inverse correlation between mTORC1/S6K and mTORC2 activities was confirmed ( Supplementary   Fig. 1a-d) . Intriguingly, the critical role of Grb10 (refs 29,30) and IRS-1 (refs 27,28) in the regulation of the mTORC2-Akt pathway was found to be restricted to insulin or IGF-1, but not PDGF or EGF stimulation ( Supplementary Fig. 1e-g) . Consistently, inhibition of mTORC1-S6K signalling by a specific S6K1 inhibitor, S6K1-I (ref. 31) , or mTORC1 inhibitor, rapamycin 11, 32, 33 , could still augment Akt activation in TSC2 −/− mouse embryonic fibroblasts (MEFs) depleted of endogenous IRS-1 and/or Grb10 ( Supplementary Fig. 1h-m) , advocating that mTORC1/S6K could exert its negative regulation of mTORC2-Akt following PDGF or EGF stimulation through uncharacterized negative feedback loop(s) other than IRS-1 and Grb10. As rictor and Sin1 are the only two unique essential mTORC2 components 13, 34 , we reasoned that the mTORC1/S6K-dependent regulation of mTORC2 might occur Sin1-FL  S6K  IB: HA-mTOR-KD   IB: Sin1-pT86   IB: GST   11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30   669  440  158  75 and anti-Flag immunoprecipitates (IP) derived from HEK293T cells transfected with the indicated Flag-Sin1 constructs (EV, empty vector control; WT, Sin1-WT; AA, Sin1-T86A/T398A; EE, Sin1-T86E/T398E). (b-d) GST pulldown assays to demonstrate that S6K phosphorylation of GST-Sin1-WT-FL (full-length) but not GST-Sin1-T86A/T398A led to impaired interaction with rictor (b), mTOR-kinase domain (KD) (c) or GβL (d). As indicated, GST-Sin1 proteins were phosphorylated by active recombinant S6K in vitro for 1 h before use as a bait to pull down HA-rictor (b), mTOR-kinase domain (KD) (c) or GβL (d) expressed in HEK293T cells. (e) Gel filtration experiments to illustrate that when compared with WT-Sin1, Sin1-EE lost interaction with the functional mTORC2 complex components in vivo. Immunoblot analysis of the indicated fractionations derived from the gel filtration experiment with HeLa cells co-transfected with HA-Sin1-WT and Flag-Sin1-EE constructs. Before running cell lysates, the molecular weight resolution of the column was first estimated by running native molecular weight markers (thyroglobulin, relative molecular mass of 669,000 (M r ∼669K); ferritin, M r ∼440K; aldolase M r ∼158K; conalbumin M r ∼75K; and ovalbumin M r ∼44K) to determine their retention times on Coomassie-stained SDS-PAGE protein gels. (f) Deletion of endogenous TSC2, which led to increased S6K kinase activity, resulted in a reduction of rictor association with Sin1. Immunoblot analysis of WCL and anti-Sin1 immunoprecipitates derived from TSC2 +/+ or TSC2 −/− MEFs. (g) Schematic representation of the indicated domains of Sin1 as well as the locations of the two Sin1 phosphorylation sites: Thr 86 is in the N-terminal domain whereas Thr 398 is located in the PH domain. (h) GST pulldown assays to depict the Sin1 domains that interact with rictor, mTOR-KD or GßL, respectively (the asterisk indicates the sizes of GST-Sin1 proteins). (i,j) GST pulldown assays to demonstrate that Sin1-T86E or -T398E mutation led to reduced interaction with rictor (i) or mTOR-KD (j), respectively. Uncropped images of blots are shown in Supplementary Fig. 9 .
through rictor or Sin1. However, S6K-dependent phosphorylation of rictor does not affect mTORC2 kinase activity 32, 35, 36 , which prompted us to investigate whether Sin1 is the primary target to mediate the regulation of mTORC2 by mTORC1/S6K.
In line with previous reports 13, 15 , insulin, IGF-1, PDGF and EGF all could effectively induce Akt Ser 473 phosphorylation in wild-type (WT) but not Sin1 −/− MEFs ( Supplementary Fig. 1n ) or Sin1-depleted TSC2 −/− cells ( Supplementary Fig. 1o ). This finding prompted us to further examine whether other than IRS-1 and Grb10, modifications of Sin1 may play a critical role in mTORC1-mediated feedback regulation of mTORC2. In support of this hypothesis, phosphorylation of Sin1 was significantly reduced on inhibition of mTORC1 or S6K, and moderately decreased by the Akt inhibitor, AktVIII (Fig. 1a ). Consistently, we detected in vivo Sin1 phosphorylation triggered by S6K1 and to a lesser extent, Akt1, but not other characterized AGC kinases ( Fig. 1b and Supplementary Fig. 2a ). Notably, S6K1 inhibition led to reduced Sin1 phosphorylation while overexpressing a WT-S6K1 ( Fig. 1c ), but not a kinase-dead-S6K1 mutant 37 ( Supplementary Fig. 2b (K)  180  115  82  64  82  64   82  64  180  115  64  49   64  49   0  30  60  90  120  240   0  15  60  120  240  30  0  15  60  120  240  30  0  15  60  120  240  30   0  8  16  24  32  40  0  8  16  24  32  40  0  8  16  24  32  40   WT  T86A  T398A   0  8  16  24  32  40   0  8  16  24  32  0  8  16  24  32  0  8  16  24  32  0  8  16  24  32 Figure 3 Sin1 phosphorylation induced by various stimuli impairs mTORC2 integrity. (a) Immunoblot (IB) analysis of whole-cell lysates (WCL) and endogenous Sin1 immunoprecipitates (IP) derived from Sin1-WT MEFs that were serum-starved for 24 h and then collected after EGF (100 ng ml −1 ) stimulation for the indicated time periods. (b) Immunoblot analysis of WCL and anti-Flag immunoprecipitates derived from Flag-Sin1-transfected HeLa cells that were serum-starved for 24 h and then collected after insulin stimulation for the indicated time periods. (c) Either Sin1-T86A or -T398A mutation impaired the dynamic interaction between Sin1 and other essential mTORC2 components. Immunoblot analysis of WCL and anti-Flag immunoprecipitates derived from HeLa cells transfected with the indicated Flag-Sin1 constructs that were serum-starved for 12 h and then treated with the EGF (100 ng ml −1 ) for the indicated time periods before collection for immunoblot analysis. (d) Either Sin1-T86A or -T398A mutation led to sustained Akt activation on EGF stimulation. Immunoblot analysis of WCL derived from HeLa cells transfected with the indicated Flag-Sin1 constructs that were serum-starved for 12 h and then treated with the EGF (100 ng ml −1 ) for the indicated time periods before collection for immunoblot analysis. (e) Rapamycin or S6K1-I treatment led to a relatively sustained Akt-pS473 on insulin stimulation. Immunoblot analysis of WCL derived from HeLa cells serum-starved for 12 h and stimulated with 100 ng ml −1 insulin before collection at the indicated time points. Where indicated, 20 nM rapamycin or 10 µM S6K1-I was added. Uncropped images of blots are shown in Supplementary Fig. 9 .
( Supplementary Fig. 2c ). In support of Sin1 being a S6K substrate, we identified two canonical AGC family kinase-recognition motifs (RxRxxpS/pT; ref. 38) located at Thr 86 and Thr 398, respectively ( Fig. 1d ). Notably, mutation of both sites to alanines abolished S6K1-mediated Sin1 phosphorylation in cells ( Fig. 1e ) or in vitro ( Fig. 1f ). Interestingly, mutation of either Thr 86 or Thr 398 to an alanine did not completely abolish the S6K-dependent phosphorylation of Sin1 ( Fig. 1e ), indicating that both T86 and T398 might be potential S6K1 sites in vivo. Importantly, phosphorylation of Thr 86 and Thr 398 was detected by mass spectrometry ( Supplementary Fig. 2d-e ). To gain further mechanistic insights into how Sin1 phosphorylation may affect mTORC2 activation under physiological conditions, we developed phospho-specific antibodies against pT86-Sin1 or pT398-Sin1, respectively ( Supplementary Fig. 2f -g). Using these antibodies we observed an increase in Sin1-pT86 and Sin1-pT398 on induction by insulin ( Fig. 1g and Supplementary Fig. 2h ), IGF-1, PDGF or EGF ( Fig. 1h ), whereas these phosphorylation events could be attenuated by inactivating S6K1 either through depleting raptor ( Fig. 1h and Supplementary Fig. 2i ), or by S6K1-I ( Supplementary  Fig. 2j ). Notably, S6K1 knockdown only partially reduced Sin1 phosphorylation ( Supplementary Fig. 2i ), suggesting that other S6K isoforms might phosphorylate Sin1. Nevertheless, recombinant S6K1 phosphorylated Sin1 in vitro ( Supplementary Fig. 2k ) and, conversely, rapamycin could attenuate Sin1-pT86 mediated by WT-S6K1 but not a rapamycin-resistant form of S6K1 (ref. 37 ; Supplementary Fig. 2l ), further supporting a role for S6K1 as a physiological kinase for Sin1.
Both Akt and S6K may phosphorylate Sin1 in a context-dependent manner
Although depletion of endogenous Akt1 also led to a moderate decrease in Sin1 phosphorylation, its effects were less compared with inhibiting S6K1 or mTORC1 in our experimental conditions ( Supplementary Fig. 2m -n). Moreover, Akt might regulate Sin1 phosphorylation indirectly through activating mTORC1/S6K (refs 11, 13) . In support of this model, Sin1 Thr 86 phosphorylation correlated positively with S6K1 activity (evidenced by pS6) but inversely with Akt phosphorylation ( Supplementary Fig. 2o -p), indicating that Sin1 phosphorylation by S6K1 might act as a physiological negative regulator of Akt phosphorylation in fibroblasts. However, this conclusion might be cellular context-dependent as a recent study has suggested Akt as the Sin1 Thr 86 phosphorylating kinase in adipocytes 39 .
To gain further mechanistic insights into upstream kinases responsible for phosphorylating Sin1, we examined the possible role of S6K versus Akt in mediating Sin1 phosphorylation on Thr 86 and Thr 398 in 3T3-L1 cells 40 . Consistent with ref. 39 , Sin1-pT86 signals were largely blocked by Akt inhibition, but only moderately reduced by inhibiting mTORC1 or S6K ( Supplementary Fig. 2q ), confirming Akt as the main Sin1 Thr 86 phosphorylating kinase in 3T3-L1 cells. However, inhibitors targeting either Akt or S6K1 led to a marked reduction in Sin1-pT398, suggesting that both Akt and S6K are involved in phosphorylating Sin1 Thr 398 in 3T3-L1 adipocytes. On the other hand, in epithelium-derived HeLa cells, in stark contrast to 3T3-L1, inhibition of mTORC1/S6K, rather than Akt, led to a more severe reduction in both Sin1-pT86 and Sin1-pT398 signals ( Supplementary Fig. 2r ), indicating that in HeLa cells, S6K, but not Akt, is the main kinase responsible for Sin1 Thr 86 and Thr 398 phosphorylation. Collectively, these results indicate that physiological upstream kinase(s) responsible for Sin1 Thr 86 or Sin1 Thr 398 phosphorylation might be tissue-specific or cellular context-dependent. A similar tissue-specific phosphorylation atlas of mouse proteins has been established 41 . Hence, adipocytes versus epithelial cells might require tightly regulated and specialized, phosphorylation-dependent intracellular signalling, thereby using distinct upstream signalling routes to regulate effector pathways such as mTORC2. As carcinomas primarily derive from epithelial cells 42, 43 , we chose to focus on understanding how regulation of mTORC2 by S6K-mediated Sin1 phosphorylation contributes to tumorigenesis in the epithelial cell settings.
Phosphorylation of Sin1 at both Thr 86 and Thr 398 dissociates Sin1 from the mTORC2 complex
As Sin1 is an essential component that governs mTORC2 integrity [13] [14] [15] , we next examined whether Sin1 phosphorylation on Thr 86 and Thr 398 affects mTORC2 function. Strikingly, compared with WT-Sin1, the Sin1 phospho-mimetic mutant (T86E/T398E, Sin1-EE) failed to interact with the essential mTORC2 components rictor, mTOR or GβL ( Fig. 2a and Supplementary Fig. 3a -c), indicating that the assembly of a functional mTORC2 complex was prevented by Sin1 phosphorylation. In support of this model, S6K1-mediated phosphorylation of Sin1-WT, but not the Sin1 phospho-deficient mutant (T86A/T398A, Sin1-AA), reduced Sin1 interaction with rictor ( Fig. 2b) , mTOR ( Fig. 2c ) and GβL ( Fig. 2d ). Notably, disruption of the Sin1/rictor interaction required Sin1 phosphorylation on both Thr 86 and Thr 398 ( Supplementary Fig. 3d ,e). To further investigate the underlying molecular mechanism(s), we performed gel-filtration assays to examine mTORC2 complex assembly in cells, and observed that WT-Sin1, but not Sin1-EE, co-eluted with mTORC2 components including rictor, mTOR and GβL ( Fig. 2e ). Furthermore, depletion of TSC2 led to elevated mTORC1/S6K activity and shifted a significant portion of Sin1 to mTORC2-free fractions ( Supplementary Fig. 3f,g) . Strikingly, the mTORC2-free Sin1 species were enriched with pT86-Sin1 ( Supplementary Fig. 3f ). Consistently, less rictor was detected in association with Sin1 in TSC2 −/− cells ( Fig. 2f ), whereas inhibiting S6K1 activity in TSC2 −/− cells by S6K1-I partially restored rictor interaction with Sin1 ( Supplementary  Fig. 3h ,i), supporting a crucial role for S6K in regulating the Sin1-rictor interaction.
To further understand the role of each Sin1 phosphorylation event in mediating mTORC2 complex organization, we truncated Sin1 into four regions ( Fig. 2g ) and observed that Sin1 mainly interacts with rictor through its amino-terminal region, with mTOR kinase domain through its PH domain, and with GβL through its N, RBD Flag-Sin1-WT Flag- Sin1-R81T   10 11 12 13 14 15 16 17 18 19 20 21   669  440  158  75   Flag-Sin1-WT   22 23 24 25 26 27 28 29 30 and PH domains ( Fig. 2h ). Interestingly, phosphorylation of Sin1 at Thr 86 in the N-terminal region abolished Sin1-N interaction with rictor ( Fig. 2i ), whereas phosphorylation on Thr 398 in the PH domain reduced Sin1 interaction with the mTOR kinase domain ( Fig. 2j Etoposide (µM) supporting that phosphorylation of both Thr 86 and Thr 398 is required to functionally inactivate mTORC2. More importantly, under physiological stimulation conditions such as EGF ( Fig. 3a and Supplementary Fig. 4a ) or insulin ( Fig. 3b and Supplementary Fig. 4b ) induction, we observed an inverse correlation between the induced Sin1 phosphorylation and a association of Sin1 with rictor or mTOR, which could be abolished by mutating either Thr 86 or Thr 398 to alanine ( Fig. 3c ), or by rapamycin treatment ( Supplementary Fig. 4c-f ), demonstrating a physiological role for Sin1 phosphorylation in negatively regulating mTORC2 function. Notably, compared with Sin1-WT, impairing Sin1 phosphorylation by mutating either Thr 86 or Thr 398 ( Fig. 3d ), inhibiting S6K activity ( Fig. 3e and Supplementary Fig. 4f ), or depleting endogenous raptor ( Supplementary Fig. 4h ,i), led to sustained Akt phosphorylation under EGF or insulin stimulation. Conversely, activating S6K by either depletion of endogenous TSC2 ( Supplementary Fig. 4j ) or genetic ablation of TSC2 ( Supplementary Fig. 4k ) resulted in reduced Akt Ser 473 phosphorylation. In keeping with previous reports 27, 44 , Akt phosphorylation in response to various stimuli was attenuated in TSC2 −/− cells with elevated S6K activity ( Supplementary Fig. 4l ), confirming a negative role for S6K-mediated phosphorylation of Sin1 in Akt activation.
Phosphorylation of Sin1 on both Thr 86 and Thr 398 suppresses mTORC2-mediated activation of Akt
Notably, Sin1 phosphorylation did not affect Sin1 stability (Supplementary Fig. 5m ,n). However, phosphorylation of Sin1 specifically reduced its interaction with the mTORC2 substrate Akt1 (Fig. 4a -c) but not with another characterized mTORC2 substrate SGK1 (refs 45,46) ( Fig. 4d-e ), nor the other AGC kinase S6K1 ( Fig. 4f-g) , which might explain why Sin1 phosphorylation leads to impaired Akt activation.
To further verify the critical roles of Sin1 phosphorylation in regulating mTORC2 kinase activity, we performed in vitro kinase assays to show that unlike Sin1-WT or Sin1-AA, immunoprecipitated Sin1-EE failed to phosphorylate GST-Akt1 in vitro, presumably owing to its deficiency in forming a functional mTORC2 complex ( Fig. 5a,b with the indicated Flag-Sin1 constructs and serum-starved for 24 h and then collected after stimulation with the indicated stimuli for 30 min for IB analysis and anti-Flag immunoprecipitation. (e) Sin1 −/− MEFs were transfected with the indicated Flag-Sin1 constructs and serum-starved overnight followed by immunoblot analysis on 100 ng ml −1 EGF stimulation for the indicated time points. (f,g) Sin1-depleted OVCAR5 cells stably expressing Sin1-WT or -R81T were serum-starved overnight followed by immunoblot analysis after treatment with 100 ng ml −1 EGF (f) or 100 nM insulin (g) for the indicated time points. Uncropped images of blots are shown in Supplementary Fig. 9 .
only the gel-filtration fractions with molecular weights corresponding to the full mTORC2 complex retained the mTORC2 kinase activity towards GST-Akt1 in vitro (Fig. 5c,d) . Strikingly, consistent with previous studies [47] [48] [49] , insulin stimulation led to an oscillated pattern of Akt activation with reduced Akt phosphorylation after prolonged treatment in various cell lines ( Supplementary Fig. 5a -c), a phenotype observed in many signalling pathways 47, 50 . However, the underlying mechanism of the oscillation of Akt phosphorylation remains not fully understood. Notably, prolonged (45 min of) insulin treatment led to a severe reduction of mTORC2-mediated in vitro phosphorylation of Akt in part by inducing pT86-Sin1 ( Fig. 5c,d ) to disrupt the mTORC2 complex integrity. More importantly, rapamycin treatment effectively restored mTORC2 complex integrity and kinase activity under prolonged EGF stimulation ( Fig. 5e ), emphasizing that S6K negatively regulates mTORC2 activity in part through phosphorylating Sin1, serving as a molecular switch to shut down EGF or insulininduced activation of mTORC2-Akt signalling in a timely fashion ( Supplementary Fig. 5d ).
Given the critical role of the mTORC2-Akt signalling in cell survival and tumorigenesis, we next examined the biological significance of S6K-mediated Sin1 phosphorylation on mTORC2 function. Consistent with in vitro kinase assay results (Fig. 5a ), Sin1-WT, but not Sin1-EE , rescued in vivo Akt Ser 473 phosphorylation in Sin1 −/− MEFs (Fig. 6a,b and Supplementary Fig. 6a; refs 13,15 ). Furthermore, in echoing the in vitro kinase results (Fig. 6c ), immunopurified endogenous Akt1 from Sin1-EE-expressing Sin1 −/− MEFs was deficient in phosphorylating the well-characterized Akt substrate crosstide 51, 52 in vitro (Fig. 6d) . Consistently, compared with Sin1-WT-expressing Sin1 −/− cells, Sin1 −/− cells expressing Sin1-EE exhibited reduced levels of phospho-FOXOs ( Fig. 6a; ref. 53 ), and are thereby more sensitive to cell death 54, 55 induced by etoposide (Fig. 6e,f and Supplementary  Fig. 6b -e) or cisplatin (Fig. 6g ). Similar apoptotic sensitization was observed after introducing Sin1-EE, in comparison with Sin1-WT, into Sin1-depleted OVCAR5 cells ( Supplementary Fig. 6f-i) , supporting a physiological role for Sin1 phosphorylation in regulating cellular survival in part through the Akt/FOXO signalling pathway 56, 57 . Supplementary Fig. 9 .
Ovarian-cancer-derived Sin1-R81T mutation exhibited elevated oncogenic activity in part through constitutive activation of mTORC2-Akt signalling Interestingly, two natural Sin1 mutations (R81T and S84L) were recently identified in ovarian cancer patients 58 and skin cancer patients, respectively (Fig. 7a ), from two publicly available cancer genome databases: the Cosmic database (http://cancer.sanger.ac. uk/cancergenome/projects/cosmic/) 59 and the CBio database (http: //www.cbioportal.org/public-portal/) 60 . Notably, these mutations seem to disrupt the canonical S6K phosphorylation motif (Fig. 7a) , and indeed we observed a significant reduction in pT86 in both Sin1-R81T ( Fig. 7b ) and S84L ( Supplementary Fig. 7a-b ) mutants, suggesting that they functionally mimicked Sin1-T86A. More importantly, a synthesized pT86-containing peptide could be efficiently recognized by the Sin1-pT86 antibody regardless of the Sin1-R81T mutation status (Fig. 7c) , excluding a secondary antibody effect. As the R81T mutant impairs the stringent AGC substrate motif, we focused on studying the pathophysiological effects of this mutant in cells.
We found that Sin1-pT86 signal was nearly abolished in the Sin1-R81T mutant in response to a wide spectrum of stimuli, including insulin, IGF-1, PDGF and EGF (Fig. 7d ). Unlike WT-Sin1 (Fig. 3b,c) , R81T-Sin1 demonstrated a relatively sustained interaction with mTORC2 components ( Fig. 7e and Supplementary Fig. 7c,d) , resulting in prolonged mTORC2 kinase activity towards phosphorylating Akt in vitro (Fig. 5d ). In keeping with these results, in response to various external stimuli including EGF ( Fig. 7f and Supplementary  Fig. 7e ), insulin ( Fig. 7g ) and PDGF ( Supplementary Fig. 7f ), there is a more sustained Akt activation in Sin1-R81T compared with Sin1-WT-expressing OVCAR5 cells. These results support a model that the R81T mutation may enhance tumorigenesis in part through augmenting Akt activation ( Supplementary Fig. 7g ).
Biologically, expression of Sin1-R81T in either Sin1 −/− MEFs or Sin1 depleted OVCAR5 cells led to elevated phosphorylation of Akt and the Akt substrate FOXOs ( Supplementary Fig. 8a,b) , which subsequently conferred resistance to etoposide ( Fig. 8a and Supplementary Fig. 8c -g) or cisplatin (Fig. 8b,c) . Moreover, reintroduction of R81T, but not WT-Sin1, significantly promoted the anchorage-independent growth of Sin1-depleted OVCAR5 cells, arguing that R81T is a gain-of-function oncogenic mutation that favours cellular transformation (Fig. 8d ). This finding was echoed by the significantly enhanced in vivo tumour formation ability of R81T-expressing OVCAR5 cells in a mouse xenograft model (Fig. 8e-g and Supplementary Fig. 8h ). Although further investigation is required, these results provide an important clinical relevance for the oncogenic role of the Sin1-R81T mutant, in part by bypassing the mTORC1-S6K-mediated negative feedback regulation on mTORC2-Akt activation. Interestingly, we observed that Sin1-R81T-expressing OVCAR5 cells are more resistant to the Akt inhibitor AktVIII ( Supplementary Fig. 8i-k) , indicating that cancer patients bearing the Sin1-R81T mutation might poorly respond to Akt or mTOR inhibitor treatments.
Given that abnormal mTORC2-Akt activities are associated with numerous human diseases 3,6,7 , impaired Sin1 phosphorylation (such as caused by the R81T mutation) might contribute to deregulated mTORC2-Akt pathway activity in many types of tissue and disease. In this regard, we found that rapamycin treatment attenuated Sin1 Thr 86 phosphorylation in splenic B cells freshly isolated from mice, leading to elevated Akt phosphorylation in vivo ( Supplementary Fig. 8l-o) . Similar results were also observed from rapamycin-treated mouse livers (Fig. 8h) . Consistently, an inverse correlation between pT86-Sin1 and pS473-Akt was observed in a panel of T-ALL cell lines as well as in ovarian cancer patient samples ( Fig. 8i and Supplementary  Fig. 8p-r) , emphasizing the possible pathological importance of the identified negative feedback mechanism in human cancer settings. However, further studies with larger sample sizes are warranted to determine whether there is a significant inverse correlation between pT86-Sin1 and pS473-Akt.
DISCUSSION
Recent studies have begun to reveal a complicated crosscommunication between the two mTOR-containing complexes mTORC1 and mTORC2, although the exact molecular mechanism(s) remain largely elusive. Here we define an independent negative feedback regulation through which S6K or Akt directly phosphorylates Sin1 to repress mTORC2 activation in epithelial cells or adipocytes, respectively, thereby providing further molecular insights into a direct and efficient strategy to timely suppress the mTORC2-Akt pathway signalling in a possible tissue and cellular context-dependent manner. Nonetheless, phosphorylation of both Thr 86 and Thr 398 of Sin1 is required for the complete inactivation of mTORC2 kinase activity in part by dissociating Sin1 from other mTORC2 components.
As illustrated in Supplementary Fig. 8s , mTORC1 could be regulated indirectly by mTORC2 in response to extracellular growth factors, or controlled by multiple in vivo signal fluxes, such as amino acids, nutrients and stresses. As frequently observed in many signalling pathways such as those initiated by Ras or PI(3)K (ref. 61) , the mTORC2-mediated growth factor signal is activated only transiently followed by a quench of the signalling through multiple negative feedback regulations to ensure that their activations are presented only in a pulse manner 62 . More significantly, the R81T mutation of Sin1 derived from an ovarian cancer patient could bypass the identified Sin1 phosphorylation-mediated negative regulation of mTORC2 owing to the lack of a Sin1 phosphorylation motif, providing a molecular mechanism for the elevated mTORC2-Akt pathway activation that could potentially promote tumorigenesis in the ovarian cancer settings. In summary, our work identified a negative regulation mechanism mediated largely by Sin1 phosphorylation on both Thr 86 and Thr 398 to specifically suppress mTORC2 integrity and kinase activity towards Akt Ser 473 phosphorylation. Moreover, we demonstrated that deregulation of this negative regulation in pathological conditions may contribute to accelerated tumour formation.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary Information is available in the online version of the paper
METHODS
Plasmids. Pact-Flag-Sin1 was obtained from S. Ishii 34 and Flag-Sin1-T86A, T398A, T86A/T398A, T86E, T398E and T86E/T398E were generated using the QuikChange XL Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer's instructions. The HA-Sin1 plasmid was a kind gift from K. Guan. MSCV-Sin1-Myc was obtained from D. D. Sarbassov. GST-Sin1, GST-Sin1-T86A, GST-Sin1-T398A and GST-Sin1-T86A/T398A were constructed by subcloning the corresponding Sin1 complementary DNAs from Pact-Flag-Sin1 into the pGEX-4T-1 vector. Myc-rictor, HA-rictor and Myc-mTOR have been described previously 32 . Plasmids that express HA-Myr-Akt1/Akt2 and HA-SGK1 60 were described previously 63 and they are well-characterized constitutively active mutant forms for the AGC kinases in which the N termini of Akt1 and Akt2 are fused with the myristoylation signal peptide derived from Src, and the SGK1 N-terminal inhibitory domain was removed. These constructs have been widely used in identifying AGC kinase substrates 63, 64 . The HA-S6K1-CA, HA-S6K1-R3A, HA-S6K1-WT and HA-S6K1-KD constructs were described previously 63 . Notably, the HA-S6K1-CA construct bears three mutations (F5A-T389E-R3A) and it is a constitutively active version of S6K1 in part owing to its insensitivity to rapamycin inhibition. The short hairpin RNA (shRNA) construct against GFP was described previously 53 . Sin1-shRNA-resistant Pact-Flag-Sin1 and MSCV-Sin1-Myc constructs were generated using the QuikChange XL Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer's instructions, with specific primer sequences listed below to generate the silent mutations: 5 -CGCAAATTGACATAGCCACCGTGCAAGATATGCAAGATATGCTTAGCAGC-3 C-3 (sense) and 5 -GGCTGCTAAGCATATCTTGCACGGTGGCTATGTCAAT-TTGCG-3 (anti-sense).
shRNAs. shRNA vectors to deplete endogenous rictor and endogenous raptor were purchased from Addgene (plasmid number: #1584 for rictor shRNA and #1858 for raptor shRNA, respectively). pLKO lentiviral expression vectors to deplete endogenous S6K1 (denoted A with the targeted sequence as 5 -TATTGGAAGTGGTGCCGATGC-3 , B with the targeted sequence as 5 -TAAGCACCTTCATGGCAAATA-3 and C with the targeted sequence as 5 -TAAGGTTGAGAAAGATGTCGC-3 ) were kind gifts from W. Hahn. The IRS-1 shRNA construct to deplete endogenous mouse IRS-1 (targeted sequence as 5 -ATATTCACATATTCTCCTGGG-3 ) was obtained from S. J. Elledge and the Grb10 shRNA construct to deplete mouse Grb10 was described previously 30 . To generate the lentiviral shRNA construct against human Sin1, the following sequences were cloned into the pLKO-puro and pLKO-hygro-lentiviral vectors (Sin1 sense: 5 -GCCACAGTACAGGATATGCTT-3 ; Sin1 anti-sense: 5 -AAGCATATCCTGTACTGTGGC-3 ).
Antibodies. All antibodies were used at a 1:1,000 dilution in 5% non-fat milk. Anti-Sin1 antibody for western blots was purchased from Millipore (07-2276). Anti-Sin1 antibody for endogenous Sin1 IP was purchased from Bethyl (S300-910). Anti-mTOR antibody (2972), anti-pSer2481-mTOR antibody (2974), anti-raptor antibody (2280), anti-GβL antibody (3274), anti-phospho-Ser473-Akt antibody (4051), anti-phospho-Thr308-Akt antibody (2965), anti-phospho-Thr450-Akt antibody (9267), anti-Akt1 antibody (2938), anti-Akt total antibody (4691), anti-phospho-Thr389-S6K antibody (9205), anti-S6K antibody (9202), anti-phospho-Akt substrate antibody (9614), anti-phospho-S6 antibody (4858), anti-pTSC2-antibody (3617), anti-TSC2 antibody (3990), anti-phospho-T24/32- Immunoblots and immunoprecipitation. Cells were lysed in EBC buffer (50 mM Tris at pH 7.5, 120 mM NaCl and 0.5% NP-40) or CHAPS buffer (for immunoprecipitation; 25 mM HEPES at pH 7.4, 150 mM NaCl, 1 mM EDTA and 0.3% CHAPS) supplemented with protease inhibitors (Complete Mini, Roche) and phosphatase inhibitors (phosphatase inhibitor cocktail set I and II, Calbiochem). The total protein concentrations of whole-cell lysates were measured by the Beckman Coulter DU-800 spectrophotometer using the Bio-Rad protein assay reagent. Same amounts of whole-cell lysates were resolved by SDS-PAGE and immunoblotted with indicated antibodies. For immunoprecipitation, 1,000 µg lysates were incubated with the indicated antibody (1-2 µg) for 3-4 h at 4 • C followed by 1 h incubation with Protein A Sepharose beads (GE Healthcare). Immunoprecipitates were washed five times with NETN buffer (20 mM Tris, at pH 8.0, 100 mM NaCl, 1 mM EDTA and 0.5% NP-40) or CHAPS buffer (25 mM HEPES at pH 7.4, 150 mM NaCl, 1 mM EDTA and 0.3% CHAPS) before being resolved by SDS-PAGE and immunoblotted with indicated antibodies. Note that for the immunoblot analysis results presented in Fig. 6b and Supplementary Figs 1e-f, 3f, 4g-k and 7c , owing to the large sample sizes to be compared side by side, which is not feasible using one SDS-PAGE gel of 15 lanes, the protein samples were, alternatively, loaded on separate SDS-PAGE gels, but transferred and blotted on the same PVDF membranes. In this experimental condition, care was taken to ensure that all of the samples are subjected to the same immunoblotting and exposure conditions, which can be directly compared to each other, as we described previously 32, 63, 65 .
Cell culture and cell viability assays. Cell culture and transfection have been described previously 66 . The WT and Sin1 −/− MEFs were described before 13 . TSC2-WT and TSC2 −/− MEFs were from B. D. Manning. 3T3-L1 cells were obtained from B. Spiegelman. Lentiviral shRNA virus packaging and subsequent infection of various cell lines were performed according to the protocol described previously 67 . Kinase inhibitors Akt 1/2 Inhibitor VIII (Calbiochem, 124018), PP242 (Sigma, P0037), rapamycin (Calbiochem, 553210) and S6K1-I (TOCRIS, 4032) were used as indicated. For cell viability assays, cells were plated at 10,000 per well in 96-well plates, and incubated with complete DMEM medium containing different concentrations of etoposide (Sigma, E1383) for 48 h. Assays were performed with the CellTiter-Glo Luminescent Cell Viability Assay Kit according to the manufacturer's instructions (Promega).
In vitro kinase assays. S6K and mTORC2 in vitro kinase assays were adapted from those described previously 68 
Mass spectrometry analysis to detect Sin1 Thr 86 phosphorylation in vivo.
The procedure was performed as described previously 32 with minor modifications. Briefly, HEK293T cells were transiently transfected with the Flag-Sin1 plasmid, and 24 hours post-transfection, cells were treated with insulin for 30 min before collection. Whole-cell lysates were collected to perform Flag immunoprecipitation. The Flag immunoprecipitates were then resolved on SDS-PAGE and visualized by colloidal Coomassie blue. The band containing Flag-Sin1 was excised and washed with 50% acetone. In-gel digestion of the protein was performed with chymotrypsin and analysed by reversed-phase microcapillary/tandem mass spectrometry (LC/MS/MS) using a LTQ Orbitrap XL (Thermo Fisher Scientific) hybrid ion trap-Orbitrap mass spectrometer as described previously 35 . MS/MS centroid spectra collected using collision-induced dissociation in a Top-6 datadependent acquisition 69 mode were searched against the concatenated target and decoy (reversed) Swiss-Prot protein database (version 2012_01) using the Sequest search engine in Proteomics Browser Software (PBS; W. S. Lane, Harvard University) with differential modifications for Ser/Thr/Tyr phosphorylation (+79.97) and differential modification of Met oxidation (+15.99, Msx). Phosphorylated and unphosphorylated peptide sequences were identified if they initially passed the following Sequest scoring thresholds against the target database: 1+ ions, Xcorr 3 2.0 Sf 3 0.4, P 3 5; 2+ ions, Xcorr 3 2.0, Sf 3 0.4, P 3 5; 3+ ions, Xcorr 3 2.60, Sf 3 0.4, P 3 5 against the target protein database with mass accuracy less than 15 ppm. Manual inspection and determination of the exact sites of phosphorylation was carried out using FuzzyIons and GraphMod software (PBS, W. S. Lane, Harvard University). False discovery rates of peptide hits (phosphorylated and non-phosphorylated) were estimated below 1.0% based on reversed database hits.
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Mass spectrometry analysis to detect Sin1 Thr 398 phosphorylation in vitro.
The mass spectrometry procedure was performed as described in the above section. Phosphorylated GST-Sin1 samples were prepared as described in the kinase assay section. Specifically, 1 µg of phosphorylated GST-Sin1 proteins was subjected to trypsin digestion before being analysed by mass spectrometry.
Gel filtration chromatography analysis. Sin1 constructs were transiently transfected into HeLa cells (three 10 cm dishes for each sample per gel filtration experiment). At 48 h post transfection, cells were washed with phosphate-buffered saline, lysed in 0.5 ml of CHAPS lysis buffer (25 mM HEPES at pH 7.4, 150 mM NaCl, 1 mM EDTA and 0.3% CHAPS) containing protease inhibitors (Complete Mini, Roche) and phosphatase inhibitors (phosphatase inhibitor cocktail set I and II, Calbiochem), and filtered through a 0.45 µm syringe filter. Total protein concentration was then adjusted to 8 mg ml −1 with CHAPS buffer and 500 µl of the lysate was loaded onto a Superdex 200 10/300 GL column (GE Lifesciences Cat. No. 17-5175-01). Chromatography was performed on the AKTA-FPLC (GE Lifesciences Cat. No. 18-1900-26) with CHAPS buffer as described previously 32 . One column volume of eluates were fractionated with 500 ml in each fraction, at the elution speed of 0.5 ml min −1 . Thirty microlitre aliquots of each fraction were loaded onto SDS-PAGE gels and detected with indicated antibodies.
To carry out the experiments presented in Fig. 5c-f , cells transiently transfected with Flag-Sin1-WT or Flag-Sin1-R81T were treated with 100 nM insulin for 45 min before harvesting in CHAPS buffer (25 mM HEPES at pH 7.4, 150 mM NaCl, 1 mM EDTA and 0.3% CHAPS) containing protease inhibitors (Complete Mini, Roche) and phosphatase inhibitors (phosphatase inhibitor cocktail set I and II, Calbiochem) and filter cleared. Twenty-five microlitres of each gel filtration fraction was incubated with 2 µg of GST-Akt-tail proteins and the in vitro kinase assays were performed as described previously 32 . Soft agar assays. The solid medium consists of two layers. The bottom layer contains 0.8% noble agar and the top layer contains 0.4% agar. Briefly, 3 5 cells were plated in the top layer. Five hundred microlitres of DMEM medium was added every other day to keep the top layer moist and 3 weeks later the cells were stained with iodonitrotetrazolium chloride for colony visualization and counting. Three independent experiments were performed to generate the error bar.
Annexin
Mouse xenograft assays. The tumorigenesis assay was performed as described previously 65 . Briefly, 3 × 10 6 cells were mixed with Matrigel (1:1) and injected into the flank of 10 male nude mice (NCRNU-M-M from Taconic, 4-5 weeks of age at purchase) for OVCAR5 cells stably expressing either Sin1-WT or the Sin1-R81T mutation. Tumour size was measured weekly with a caliper, and the tumour volume was determined with the formula: L × W 2 × 0.52, where L is the longest diameter and W is the shortest diameter. After 28 days, mice were euthanized and in vivo solid tumours were dissected and tumour weights were measured and recorded.
Immunohistochemistry and immunostaining analyses of tissue microarrays.
Formalin-fixed and paraffin-embedded tissue microarrays of human ovarian tissues and ovarian cancer tissues were purchased from Imgenex (IMH-347). Immunohistochemical stainings for Akt-pS473 and Sin1-pT86 were performed as described previously 70 . The Akt-pS473 antibody for immunohistochemistry was purchased from Cell Signaling Technology (#4060) and the Sin1-pT86 antibody was generated by collaboration with Cell Signaling Technology. Statistical analysis was performed by Fisher's exact analysis.
Sample size, randomization and blinding for animal studies. For mouse xenograft assays in Fig. 8e-g and Supplementary Fig. 8h, 10 mice were included in each group to determine the statistical significance. No method of randomization was used to determine how samples/animals were allocated to experimental groups and processed. The investigators were not blinded to allocation during experiments and outcome assessment. Figures 1a,f,g, 2f,h, 3a,c, 4a ,b,f, 5d,f and 7b,e,g and Supplementary Figs 1a,l,m, 2c,p, 3a-d, 4c,d,g,i, 6d ,e, 7a,b and 8c,d are representative images from two independent experiments. Figs 1b,e, 2a, 3b, 5a and 6a are representative images from three independent experiments. The error bars in Figs 6d,e,g and 7a,b,d and Supplementary Figs 6b,c, 8e -g, and 8i-k are obtained from three independent experiments. Supplementary Fig. 8m is a representative image from 4 independent experiments. For the xenograft experiments presented in Fig. 8e-g and Supplementary Fig. 8h , each cell line was injected into 10 mice to determine the statistical significance. The western blot images from Fig. 8h were derived from a single experiment owing to the limited amount of mice; however, 4 mice in each group were included as internal controls. Figure S1 Sin1 plays a critical role in negative regulation of Akt-Ser473 phosphorylation in response to PDGF or EGF stimulation independent of Grb10 or IRS-1. a. Inhibiting mTORC1/S6K by various inhibitors led to elevated Akt-Ser473 phosphorylation. Immunoblot (IB) analysis of whole cell lysates (WCL) derived from HeLa cells that were serum-starved for 24 hours and then collected after insulin stimulation for 30 minutes. Where indicated, the kinase inhibitors (AktVIII: 10 mM, PP242: 1 mM, Rapamycin: 20 nM, S6K1-I: 10 mM) were added together with insulin (100 nM). DMSO was used as a negative control. b. Depletion of endogenous S6K1 or endogenous Raptor led to elevated Akt-Ser473 phosphorylation. IB analysis of WCL derived from HeLa cells infected with the indicated lentiviral shRNA constructs. 24 hours post-infection, cells were selected with 1 mg/ml puromycin for 72 hours to eliminate non-infected cells. c-d. Depletion of endogenous TSC2, which activates S6K, led to a reduction in Akt-Ser473 phosphorylation. IB analysis of WCL derived from WT or TSC2 -/-MEFs (c) or HeLa cells depleted of endogenous TSC2 via lentiviral infections (d). e. Depletion of endogenous Grb10 did not significantly affect Akt-Ser473 phosphorylation in response to PDGF or EGF. TSC2 -/-MEFs were infected with the shGrb10 (with shGFP as a negative control) lentiviral construct and selected with 1 mg/ml puromycin for 72 hours to eliminate non-infected cells. Afterwards, the generated various TSC2 -/-MEFs were serum-starved for 24 hours and then collected after stimulation with increasing dose of the indicated stimuli for 30 minutes for IB analysis. f-g. Depletion of endogenous IRS-1 or IRS-1/Grb10 double knockdown did not significantly affect Akt-Ser473 phosphorylation in response to PDGF or EGF. TSC2 -/-MEFs were infected with the shIRS-1 (with shGFP as a negative control) lentiviral construct and selected with 1 mg/ ml puromycin for 72 hours to eliminate non-infected cells (f). The IRS-1depleted TSC2 -/-MEFs were subsequently infected with the shGrb10 (with shGFP as a negative control) lentiviral construct to generate IRS-1/Grb10 double-depletion cell lines (g). Afterwards, the generated various TSC2 -/-MEFs were serum-starved for 24 hours, stimulated with increasing doses of the indicated stimuli (insulin: 100 nM; IGF-1: 100 ng/ml and PDGF: 100 ng/ml for 30 minutes; or EGF: 100 ng/ml for 10 minutes) then lysed for IB analysis. h-i. IB analysis to demonstrate the IRS-1 (h) or Grb10 (i) depletion efficiency. TSC2 -/-MEFs were infected with either shIRS-1 or shGrb10 (with shGFP as a negative control) lentiviral constructs and selected with 1 mg/ml puromycin for 72 hours to eliminate non-infected cells. Afterwards, the whole cell lysates were collected for IB analysis. j-m. Akt-Ser473 phosphorylation could still be augmented upon S6K1-I (j) or rapamycin (k) inhibitor treatment in cells depleted of both endogenous IRS-1 and Grb10. TSC2 -/-MEFs were infected with shIRS-1 or shGrb10 (with shGFP as a negative control) lentiviral shRNA constructs and selected with 1 mg/ml puromycin for 72 hours to eliminate non-infected cells. The IRS-1-depleted TSC2 -/-MEFs were subsequently infected with the shGrb10 (with shGFP as a negative control) lentiviral shRNA construct to generate the IRS-1/Grb10 double-depletion cell lines (l-m). Afterwards, the generated various TSC2 -/-MEFs were treated with 10 mM S6K inhibitor (j, l) or 20 nM rapamycin (k, m) for 12 hours before collecting the whole cell lysates for IB analysis. n. WT or Sin1 -/-MEFs were serum-starved for 24 hours and then collected after stimulation with the indicated stimuli for 30 minutes for IB analysis. o. Depletion of endogenous Sin1 in TSC2 -/-MEFs led to an abolishment of Akt-Ser473 phosphorylation. IB of WCL derived from shGFP-or shSin1-TSC2 -/-MFEs that were serum starved for 12 hours and then treated with the indicated stimuli for the indicated time periods before harvesting for IB analysis. Specifically, the doses of stimuli used are listed below: insulin (100 nM), IGF-1 (100 ng/ ml), PDGF (100 ng/ml) and EGF (100 ng/ml). Other than the indicated time points for EGF, cells were treated for 30 min with insulin, IGF-1 or PDGF before harvesting.
Repeatability of experiments.
Figure S2 S6K1 is the major physiological kinase responsible for Sin1 phosphorylation at both T86 and T398 sites in a tissue-specific or contextdependent manner. a. AGC kinases in Fig. 1b were active, as illustrated by their comparable capability to phosphorylate Rictor in cells. Immunoblot (IB) analysis of whole cell lysates (WCL) and immunoprecipitates derived from 293T cells transfected with Myc-Rictor and indicated HA-tagged constitutive active AGC family kinases. b. A dominant negative form of S6K (K/R) mutant could block Sin1 phosphorylation in 293T cells. IB analysis of WCL and immunoprecipitates derived from 293T cells transfected with Flag-Sin1 and HA-S6K1-WT or a constitutive active form of S6K1 in the presence or absence of 20 nM rapamycin. c. Depletion of endogenous TSC2, which led to elevated S6K kinase activity, resulted in increased Sin1 phosphorylation in cells. IB of WCL and Flag immunoprecipitates derived from shGFP-or shTSC2-HeLa cells that were transfected with the Flag-Sin1 construct (pcDNA3 plasmid was used as a negative control). 30 hours post-transfection, cells were serum starved for 24 hours and then treated with insulin for 30 minutes before harvesting for IB analysis. d. Schematic representation of the Sin1 peptide where the T86 site was identified to be phosphorylated in vivo by the mass spectrometry analysis. Please refer to the methods section "Mass Spectrometry Analysis" for experimental details. e. Schematic representation of the Sin1 peptide where the T398 site was identified to be phosphorylated in vitro by S6K1 using the mass spectrometry analysis. Please refer to the methods section "Mass Spectrometry Analysis" for experimental details. f. Characterization of the generated Sin1-pT86 antibody. IB analysis of WCL and Flag immunoprecipitates (IP) derived from 293T cells transfected with HA-S6K1 and the indicated Flag-Sin1 constructs, by blotting with the generated phospho-Sin1-T86 antibody (Sin1-pT86) used in the rest of the studies in this paper. g. Characterization of the generated Sin1-pT398 antibody. IB analysis of Flag-IP derived from 293T cells transfected with HA-S6K1 and the indicated Flag-Sin1 constructs, by blotting with the generated phospho-Sin1-T398 antibody (Sin1-pT398) used in the rest of the studies in this paper. h. Sin1-pT398 signals could be induced by insulin in vivo. IB analysis of Flag-IP derived from HeLa cells transfected with the Flag-Sin1 construct by the generated Sin1-pT398 antibody. Where indicated, 100 nM insulin was added for 30 min prior to cell collection after overnight serum starvation. i. Depletion of endogenous Raptor or endogenous S6K1 resulted in an decrease in Sin1 phosphorylation in vivo. IB analysis of WCL and Flag-IP derived from Flag-Sin1-transfected HeLa cells that were previously infected with the indicated lentiviral shRNA to deplete endogenous Raptor or S6K1. 24 hours post transfection, cells were serum starved for another 24 hours followed by EGF stimulation (100 ng/ml) for 10 minutes before harvesting for IB analysis. j. The S6K1 inhibitor, S6K1-I, could partially block Sin1 phosphorylation induced by insulin, IGF-1, PDGF or EGF. IB analysis of WCL and Flag-IP derived from HeLa cells transfected with Flag-Sin1. 24 hours post transfection, cells were serum starved for another 12 hours followed by treatment with different stimuli (insulin: 100nM, IGF-1: 100 ng/ml, PDGF: 100 ng/ml for 30 minutes or EGF: 100 ng/ml for 10 min) in the presence or absence of 10 mM S6K1 inhibitor (S6K1-I) before harvesting for IB analysis. k. S6K phosphorylates Sin1 on T86 in vitro. GST-Sin1 was incubated with recombinant active S6K protein as described in the in vitro kinase assay section. About 20 ng of the GST-Sin1 was resolved on SDS-PAGE and blotted with the Sin1-pT86 antibody. l. Rapamycin could block WT-S6K, but not the rapamycin resistant form of S6K (CA), in phosphorylating Sin1 in vivo. IB analysis of WCL and Flag-IP derived from 293T cells transfected with Flag-Sin1 and HA-S6K1-WT (WT) or S6K1 (CA) in the presence or absence of 20 nM rapamycin. m. At endogenous levels, Sin1 phosphorylation was attenuated upon mTORC1 or S6K inhibition. IB analysis of WCL derived from foreskin fibroblasts that were serum-starved for 24 hours and then collected after stimulation with 10% FBS for 30 minutes. Where indicated, the indicated kinase inhibitors (AktVIII: 10 mM, PP242: 1 mM, Rapamycin: 20 nM, S6K1-I: 10 mM) were added together with insulin (100 nM). DMSO was used as a negative control. n. Sin1 phosphorylation was markedly decreased when endogenous Akt1 and S6K1 were depleted simultaneously. IB analysis of WCL and Flag-IP derived from Flag-Sin1transfected HeLa cells depleted of endogenous Akt1, Akt2 or together with S6K1. o. Rapamycin could partially restore Akt-pSer473 in TSC2 -/-MEFs in part via reducing Sin1 phosphorylation in vivo. IB analysis of WCL derived from WT or TSC2 -/-MEFs. Where indicated, cells were treated with 10 mM S6K inhibitor (S6K1-I) or 20 nM rapamycin before collecting WCL for IB analysis. p. Rapamycin could partially block in vivo Sin1 phosphorylation induced by insulin in primary foreskin human fibroblasts. IB analysis of WCL derived from primary foreskin fibroblasts that were serum starved for 24 hours followed by insulin stimulation (100 nM) for 30 minutes with or without rapamycin (20 nM) before harvesting for IB analysis. q. In 3T3-L1 adipocytes, Akt is the major kinase for Sin1-T86 phosphorylation, while both Akt and S6K are mediating Sin1-T398 phosphorylation. IB analysis of WCL derived from 3T3-L1 cells that were serum starved for 24 hours before addition of 100 nM insulin for 30 min together with the indicated inhibitors (AktVIII: 10 mM, PP242: 1 mM, rapamycin: 20 nM, S6K1-I: 10 mM). r. In HeLa cells, both S6K1 and Akt are involved in phosphorylating Sin1-T86, whereas S6K1 is the major kinase for Sin1-T398 phosphorylation. IB analysis of WCL derived from HeLa cells that were serum starved for 24 hours before addition of 100 nM insulin for 30 min together with the indicated inhibitors (AktVIII: 10 mM, PP242: 1 mM, rapamycin: 20 nM, S6K1-I: 10 mM). Figure S4c ,d. g. Rapamycin or S6K1-I treatment led to a relatively sustained Akt activation upon EGF stimulation. IB analysis of WCL derived from Sin1 WT MEFs stimulated with EGF with indicated inhibitors. MEFs were serum starved for 12 hours and stimulated by 100 ng/ml EGF. Where indicated, cells were treated with 20 nM rapamycin or 10 mM S6K inhibitor (S6K1-I) for 2 hours before adding EGF and collecting the WCL at the indicated time points. h-i. Upon insulin or EGF stimulation, depletion of endogenous Raptor led to an elevated Akt-Ser473 phosphorylation while depletion of endogenous TSC2 caused a reduction in Akt-Ser473 phosphorylation. IB analysis of WCL derived from shGFP-or shRaptor-(h,i) or shTSC2 (i,j). HeLa cells that were serum starved for 24 hours and then treated with insulin (h and j) or EGF (i) for the indicated time periods before harvesting for IB analysis. k. Deletion of endogenous TSC2 led to attenuated Akt-Ser473 phosphorylation induced by insulin. IB analysis of WCL derived from TSC2 +/+ or TSC2 -/-MFEs that were serum starved for 18 hours and then treated with insulin for the indicated time periods before harvesting for IB analysis. l. Deletion of endogenous TSC2 led to attenuated Akt-Ser473 phosphorylation in response to insulin, IGF-1, PDGF or EGF stimulation. IB analysis of WCL derived from TSC2 +/+ or TSC2 -/-MFEs that were serum starved for 12 hours and then treated with the indicated stimuli for the indicated time periods before harvesting for IB analysis. Specifically, the doses of stimuli used are listed below: insulin (100 nM), IGF-1 (100 ng/ml), PDGF (100 ng/ml) and EGF (100 ng/ml). Other than the indicated time points for EGF, cells were treated for 30 min with other three stimuli before harvesting. m. Sin1 phospho-mimetic mutant (Sin1-EE) exhibited similar half-life with Sin1-WT. IB analysis of WCL derived from HeLa cells transfected with the indicated Flag-Sin1 constructs and harvested at the indicated time periods of CHX treatments (100 µg/ml). Mdm2 blots were provided as a control to indicate that CHX treatment was working. n. Depletion of endogenous TSC2, which resulted in elevated S6K kianse activity and subsequently increased Sin1 phosphorylation, did not lead to noticeable changes on the stability of endogenous Sin1. IB analysis of WCL derived from HeLa cells depleted of TSC2 via lentiviral infections (with shGFP as a negative control). Cells were harvested at the indicated time periods of CHX treatments (100 µg/ml). Mdm2 blots were provided as a control to indicate that CHX treatment was working. Figure 7f . f. The Sin1-R81T mutation led to a relatively sustained Akt activation under PDGF stimulation. OVCAR5 ovarian cancer cells were depleted of endogenous Sin1 by shRNA constructs followed by re-introduction of Sin1-WT or the Sin1-R81T mutant via infection with the MSCV-retroviral vectors. The resulting cells were serum starved overnight followed by the addition of 100 ng/ml PDGF. Cells were harvested for IB analysis at the indicated time periods. g. A proposed model to describe how the ovarian cancer-derived Sin1-R81T mutation might protect the mTORC2 kinase from the negative regulation by phosphorylation of Sin1 on both the T86 and T398 sites. Specifically, the Sin1 R81T mutation led to elevated Akt S473 phosphorylation and subsequent Akt activation by bypassing the Sin1 phosphorylation mediated negative regulation of mTORC2/Akt signaling. 
